glp 1 agonist new Frontiers The Unstoppable Rise of GLP-1

Description

Ann Intern Med

These medications, when used correctly with proper medical supervision and lifestyle modifications, can be genuinely life-changing

The follow-up substance, semaglutide, has been developed into Ozempic as a diabetes treatment and Wegovy as an obesity treatment

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

Brain insulin resistance may indeed play a role in the pathophysiology of cognitive disorders, and addressing this may be a mechanism through which GLP-1RAs act pro-cognitively 35